Ntrk1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1) encodes the high-affinity nerve growth factor (NGF) receptor, also known as TrkA. This receptor tyrosine kinase is essential for the development and survival of nociceptive and thermoceptive neurons. NTRK1 is a major therapeutic target for peripheral neuropathies and has been implicated in neurodegeneration.
| Property |
Value |
| Gene Symbol |
NTRK1 |
| Full Name |
Neurotrophic Receptor Tyrosine Kinase 1 |
| Chromosomal Location |
1q21-q22 |
| NCBI Gene ID |
4914 |
| Ensembl ID |
ENSG00000164330 |
| UniProt ID |
P04629 |
| OMIM |
191315 |
| Property |
Value |
| Protein Name |
TrkA (Tropomyosin receptor kinase A) |
| Molecular Weight |
~140 kDa (796 amino acids) |
| Subcellular Localization |
Cell membrane, endosomes, nucleus |
| Protein Family |
Trk family (TrkA, TrkB, TrkC) |
¶ Domain Structure
- Extracellular domain: Leucine-rich motifs, Ig-like domains for ligand binding (NGF)
- Transmembrane domain: Single pass membrane protein
- Cytoplasmic domain: Tyrosine kinase domain (catalytic), C-terminal tail
- Nerve growth factor receptor: High-affinity binding to NGF
- Neuronal survival: Activates PI3K/Akt and MAPK/ERK pathways
- Nociception: Essential for pain sensation neurons
- Developmental biology: Axonal guidance, neuron differentiation
- Synaptic plasticity: Regulates dendritic spine formation
¶ Hereditary Sensory and Autonomic Neuropathy (HSAN)
- NTRK1 mutations cause HSAN type 4 (CIPA - congenital insensitivity to pain with anhidrosis)
- Autosomal recessive inheritance
- Loss-of-function mutations lead to inability to sense pain, temperature
- Associated with developmental abnormalities
- NGF and TrkA signaling is impaired in AD
- NGF therapy has been explored to support cholinergic neurons
- TrkA activation may protect against amyloid toxicity
- NGF supports dopaminergic neuron survival
- NTRK1 signaling may be protective
- Gene therapy approaches using NGF/TrkA
- TrkA antagonists for pain management
- Anti-NGF antibodies (tanezumab) in clinical trials for chronic pain
| Approach |
Status |
Description |
| NGF/TrkA agonists |
Clinical trials |
NGF for ALS, diabetic neuropathy |
| Anti-NGF antibodies |
Phase 3 |
Tanezumab for chronic pain |
| Gene therapy |
Preclinical |
AAV-NGF for AD |
| Small molecule agonists |
Research |
Small molecule TrkA activators |
- Hempstead BL. (2002). The many faces of p75NTR. Curr Opin Neurobiol. 12(3):260-7. https://doi.org/10.1016/s0959-4388(02)00321-5
- Matusica D, et al. (2008). NGF and proNGF signaling in neurons. Mol Neurobiol. 38(2):79-96. https://doi.org/10.1007/s12035-008-8033-4
- Tuszynski MH, et al. (2005). Nerve growth factor gene therapy for Alzheimer's disease. Gene Ther. 12(7):546-51. https://doi.org/10.1038/sj.gt.3302585
- Indo Y. (2001). Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): mutations and polymorphisms in NTRK1 (NGEF receptor). Hum Mutat. 17(5):321-31. https://doi.org/10.1002/humu.1124
The study of Ntrk1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] NTRK1 and pain and neurodegeneration. PMID:24790033